About MAPS

Who we are

Researchers of Psychedelics, Leaders of Change.

Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit organization specializing in research and education that develops medical, legal, and cultural shifts benefiting the careful uses of psychedelics and marijuana for mental and spiritual healing.

In other words, we’ve dedicated the last 35 years to changing the way people think of, talk about, and consume psychedelics through research, education, and advocacy.

Take a Trip
Down Memory Lane.

After decades of fundamental research, there was a cultural struggle over psychedelics in the United States. Just as psychiatrists, psychologists, and other researchers were making incredible headway on their studies of compounds like LSD and psilocybin (among others), the U.S. government criminalized these substances, blocking research across the globe.

Enter our founder, Rick Doblin, Ph.D.. Knowing the DEA would move onto criminalizing MDMA, Rick (along with Alise Agar and Debby Harlow) started a nonprofit in 1984, the Earth Metabolic Design Lab. They filed a lawsuit to prevent the DEA’s effort to classify MDMA as a Schedule I substance. Unfortunately, the DEA rejected the recommendation of the judge to keep the therapeutic use of MDMA legal. But hope was not lost.

By creating MAPS in 1986, Rick was able to continue researching the healing potential of MDMA and other psychedelics. Over the course of the past 35 years, MAPS has raised over $130 million for psychedelic research and education.

1972

The Awakening

Our founder, Rick Doblin, Ph.D., has his first experience with LSD, giving him a glimpse of the profound connection between heart and mind made possible by psychedelics. From that moment on, Rick dedicated his life to becoming a legal psychedelic therapist, envisioning a healthier, more sustainable and loving world.
1986

MAPS is Born

One year after MDMA is deemed illegal by the FDA, Rick founded MAPS as a research and educational organization with the goal of proving to the world (and the US government) that when coupled with therapy, psychedelics were an effective PTSD treatment.
1990

Change
in the Wind

The FDA introduces a new group to oversee psychedelic research protocols, opening the doors to modern psychedelic science. This year also marks the first major psychedelic conference hosted by MAPS, “Regulation or Prohibition: Psychedelics in the 1990s.”
2004

Let the Trials Begin

Under the leadership of drug development expert, Amy Emerson, MAPS begins focusing on clinical trials to study the effect of MDMA-assisted therapy on PTSD.
2014

MAPS PBC
is Born

In 2014, the MAPS Public Benefit Corporation (MAPS PBS) was founded in anticipation of FDA approval of MDMA-Assisted Therapy for PTSD. This year is also when MAPS published results from the first study of LSD therapy in over 40 years.
2017

Psychedelic Science 2017 is Born

In this historic six-day global gathering, the international scientific community came together to share and discuss research for psychedelic-assisted therapy. With over 3,000 attendees, Psychedelic Science 2017 featured simultaneous tracks of presentations by leading and up-and-coming international researchers in the multidisciplinary field of psychedelic science and medicine.
2019

TED
meets MAPS

MAPS founder Rick Doblin, Ph.D., presented the first official TED Talk about psychedelics. MAPS published results from the combined analysis of six Phase 2 studies of MDMA-assisted therapy for PTSD.
2021

2021
& Beyond

With Nature Medicine’s publication of our first FDA Phase 3 trial of MDMA-assisted therapy for PTSD, MAPS continues to be the leader of psychedelic research.

Our
Never-Ending
Dedication to Diversity

At MAPS, we’re committed to creating an inclusive workplace, and fully recognize that diversity is not just a goal, but an ongoing mission. We provide equal employment opportunities to support a work environment free from discrimination on the basis of race, religious creed, color, national origin, ancestry, physical disability, mental disability, medical condition, genetic information, marital status, sex, gender, gender identity, gender expression, age, sexual orientation, military and veteran status, arrest or conviction record, and any other basis prohibited by law.

The Movement
In Action

Our job is incomplete until we’re able to provide access and education to everyone. The MAPS Policy & Advocacy Department works with a wide range of communities to make psychedelic research, education, and care more accessible. Thanks to our work with various advocacy groups, we continue to work towards decriminalisation and regulation of all drugs. Only when we start with social, radical, and environmental justices can we offer true healing to everyone who needs it.

The Minds
Behind The Movement

Over the past three decades, we’ve assembled a team of passionate professionals who have helped facilitate groundbreaking studies, policy change, and radical healing.

Board of Directors

Rick Doblin, Ph.D., Founder and Executive Director

Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master’s thesis on a survey of oncologists…
Meet Rick

David Bronner, Board of Directors

Independent Voting Member David Bronner is Cosmic Engagement Officer (CEO) of Dr. Bronner’s, the top-selling brand of natural soaps in North America and producer of a range of organic body care and food products. He is a grandson of company founder, Emanuel Bronner, and a fifth-generation soapmaker. David and Michael established Dr. Bronner’s as a…
Meet David